House committee to vote on China investment and in-licensing restrictions

Starting Monday, the House Rules Committee will vote on proposals to add biotechnology to an outbound investment screening regime, enhance pharmaceutical supply chain security, and create a national biotechnology strategy. The proposals are among over 1,100 amendments to the 2027 National Defense Authorization Act that have been submitted to the Rules Committee.

Beyond attempting to roll back China’s integration into the global biopharmaceutical ecosystem, the amendments reflect a growing consensus in Congress that U.S. biotech and biomanufacturing need greater federal support...